Skin Infection News and Research

RSS

Lesser toe deformities should be treated early: Literature review

While deformities of the lesser toes can be very painful, there are numerous surgical and nonsurgical treatments for these conditions that are usually quite effective.

2 Aug 2011

Lytix Biopharma completes two LTX-109 Phase I/IIa studies in MRSA, Gram+ skin infections

The Norwegian pharmaceutical company Lytix Biopharma today announces the successful completion of two Phase I/IIa studies with the topical antimicrobial drug Lytixar - one for nasal decolonisation of MRSA / MSSA bacteria and one for treatment of Gram+ skin infections.

26 May 2011

MRSA superbug detected in bed bugs and supermarket meats: Report

Scientists have made an alarming discovery. They have found that bedbugs can carry the staph “superbug” MRSA (Methicillin-Resistant Staphylococcus aureus).

15 May 2011

MicroPhage receives FDA clearance for KeyPath MRSA/MSSA Blood Culture Test

The U.S. Food and Drug Administration today cleared the first test for Staphylococcus aureus infections that is able to quickly identify whether the bacteria are methicillin resistant or methicillin susceptible.

7 May 2011

FDA warns four firms to stop making unproven MRSA prevention claims

The U.S. Food and Drug Administration issued four warning letters to companies that manufacture and market over-the-counter (OTC) drug products, including hand sanitizers, that claim to prevent infection from methicillin-resistant Staphylococcus aureus bacteria (MRSA).

21 Apr 2011

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.

20 Apr 2011

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study (DISCOVER-1) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). The pivotal study is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

20 Apr 2011

Positive results from Nabriva's BC-3781 Phase II trial in ABSSSI

Nabriva Therapeutics today announced the successful results of a Phase II clinical trial of BC-3781 in acute bacterial skin and skin structure infections.

18 Apr 2011

Drug resistant bug plaguing the meat industry: Study

It has been found that nearly half of the meat and poultry (47 percent) sold in U.S. grocery stores is contaminated with Staphylococcus aureus (“Staph”), a bacteria linked to a wide range of human diseases, and this bacteria is resistant to at least three classes of antibiotics in more than half (52 percent) of contaminated samples. This comes from a nationwide study by the Translational Genomics Research Institute (TGen) published this week in the journal Clinical Infectious Diseases.

17 Apr 2011

Study finds 47% of meat and poultry samples contaminated with S. aureus

Drug-resistant strains of Staphylococcus aureus, a bacteria linked to a wide range of human diseases, are present in meat and poultry from U.S. grocery stores at unexpectedly high rates, according to a nationwide study by the Translational Genomics Research Institute.

15 Apr 2011

Orthopaedic surgeon: Broken bones and itching more common during spring weather

Spring weather signals the start of many outdoor activities as people of all ages eagerly embrace the change in weather. Paul Prinz, MD, orthopaedic surgeon at Gottlieb Memorial Hospital, part of Loyola University Health System says, "Broken bones and fractures occur year 'round but the change in seasons always creates an increase of patients in our offices."

8 Apr 2011

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Optimer Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID, in the United States.

6 Apr 2011

New ‘nanotech’ weapon against drug-resistant superbugs

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].

3 Apr 2011

Study finds significant increase in MRSA infections during summer, autumn months

A new study from Rhode Island Hospital has found a significant increase in the occurrence of methicillin-resistant Staphylococcus aureus infections in the summer and autumn months.

25 Mar 2011

Research: Used instrument can pose dangerous health risk in children

Research has shown that playing a musical instrument can help nourish, cultivate, and increase intelligence in children, but playing a used instrument also can pose a potentially dangerous health risk.

15 Mar 2011

Proper wound care may treat skin infections effectively than antibiotics in children with MRSA

When it comes to curing skin infected with the antibiotic-resistant bacterium MRSA, timely and proper wound cleaning and draining may be more important than the choice of antibiotic, according to a new Johns Hopkins Children's Center study. The work is published in the March issue of Pediatrics.

21 Feb 2011

RF-induced heat therapy could help treat common parasitic skin infection

Scientists are hoping that heat therapy could eventually replace a complex drug regimen as the first-line treatment of a parasitic skin infection common in tropical and subtropical regions of the world.

11 Feb 2011

Dermatologists urge athletes to be aware of most common skin infections

Team sports have a long history of fostering cooperation, camaraderie and a healthy competitive spirit among athletes. But the closeness that brings athletes together also can create an environment for a host of contagious skin infections. Now, dermatologists are urging teammates and coaches to be aware of the most common skin conditions caused by bacteria, viruses and fungi that occur in athletes and educating them on how to prevent a widespread outbreak.

5 Feb 2011

IDSA releases MRSA treatment guidelines

Physicians now have help in their battle against methicillin resistant Staphylococcus aureus (MRSA), a potentially deadly infection that initially was limited to hospitals and health care facilities but has become a growing problem in healthy children and adults. The Infectious Diseases Society of America (IDSA) has released its first guidelines for the treatment of increasingly common MRSA infections.

7 Jan 2011

New research sheds light on complex regulatory pathways for effective innate immune system

New research by scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences reveals that the immune system has an effective backup plan to protect the body from infection when the "master regulator" of the body's innate immune system fails.

21 Dec 2010